Pharma Sentiment In 2026

Biopharma companies are operating in tumultuous times. The confluence of geopolitical upheaval, new drug pricing policies and the rise of AI is hitting drugmakers already bracing for the loss of exclusivity on many of their biggest products, contributing to waves of restructurings and layoffs.

Inside the Report: Top 5 Strategic Takeaways

• Restructuring: Why most organizations have already reshuffled, and why more change is coming.
• AI & Digital Tools: How teams are adopting AI at pace, and where "tool overload" is holding back real value.
• Drug Pricing & MFN: How most-favoured-nation pricing is reshaping global launch sequencing and pushing European prices upward.
• Market Access: The budget constraints and hurdles leaders say are impacting patient access.
• Geopolitical Readiness: Why so few organisations feel confident in their contingency planning.

Essential reading for: Senior pharmaceutical leaders shaping the future of pharmaceutical commercialization, market access, marketing, medical affairs, patient engagement and digital & technology integration.